Stati Uniti - inglese - NLM (National Library of Medicine)

hospira, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 10 mg in 1 ml - hydromorphone hydrochloride injection [high potency formulation (hpf)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. patients must remain on around-the-clock opioids while administering hydromorphone hydrochloride injection [high potency formulation (hpf)]. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ see warnings and precautions (5.2)]

Stati Uniti - inglese - NLM (National Library of Medicine)

specgx llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride extended-release tablets are indicated for the management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve hydromorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or

Stati Uniti - inglese - NLM (National Library of Medicine)

purdue pharma lp - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 5 mg in 5 ml - dilaudid oral solution and dilaudid tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve dilaudid oral solution and dilaudid tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expectedto be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid oral solution and dilaudid tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.6)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including

Stati Uniti - inglese - NLM (National Library of Medicine)

tagi pharma, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride tablets, usp are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use   because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve hydromorphone hydrochloride tablets, usp for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: •  have not been tolerated, or are not expected to be tolerated, • have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets, usp are contraindicated in patients with: •  significant respiratory depression [see warnings and precautions (5.6)] • acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] • known or suspected gastrointestinal obstruction, including paralyti

Stati Uniti - inglese - NLM (National Library of Medicine)

ethex corporation - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - tablet - 2 mg - hydromorphone hydrochloride tablets are indicated for the management of pain in patients where an opioid analgesic is appropriate. hydromorphone hydrochloride tablets are contraindicated in patients with a known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. hydromorphone hydrochloride tablets are also contraindicated for use in obstetrical analgesia. hydromorphone hydrochloride tablets contain hydromorphone, a schedule ii controlled opioid agonist. schedule ii opioid substances which include morphine, oxycodone, oxymorphone, fentanyl, and methadone have the highest potential for abuse and risk of fatal overdose. hydromorphone can be abused and is subject to criminal diversion. opioid analgesics may cause psychological and physical dependence. physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug. physical dependence usually does not occur to a clinically sign

Stati Uniti - inglese - NLM (National Library of Medicine)

precision dose inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride tablets, usp are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve hydromorphone hydrochloride tablets, usp for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride tablets, usp are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.5)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - known or suspected gastrointestinal obstruction, including paralytic il

Stati Uniti - inglese - NLM (National Library of Medicine)

stat rx usa llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 2 mg - hydromorphone hydrochloride tablets usp are indicated for the management of pain in patients where an opioid analgesic is appropriate. hydromorphone hydrochloride tablets are contraindicated in: patients with known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. hydromorphone hydrochloride tablets are also contraindicated for use in obstetrical analgesia. hydromorphone is an opioid agonist of the morphine-type. such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. hydromorphone hydrochloride tablets can be abused in a manner similar to other opioid agonists, legal or illicit. this should be considered when prescribing or dispensing hydromorphone hydrochloride tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. prescribers should monitor all patients receiving opioids for si

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

as kalceks - hydromorphone hydrochloride - solution for injection/infusion - hydromorphone

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

as kalceks - hydromorphone hydrochloride - solution for injection/infusion - hydromorphone

Canada - inglese - Health Canada

sandoz canada incorporated - hydromorphone hydrochloride - solution - 2mg - hydromorphone hydrochloride 2mg - opiate agonists